Exciting Data Presentation at the Asian Conference
SAB Biotherapeutics, Inc. (NASDAQ: SABS), a cutting-edge biopharmaceutical company specializing in developing innovative therapies for autoimmune diseases, announced that it will present significant data regarding its lead program, SAB-142. This event will take place at the 2nd Asian Conference on Innovative Therapies for Diabetes Management (ATTD-Asia) in Singapore, running from December 9 to 11, 2025.
Highlights of SAB-142 Development Progress
The presentations at this prestigious conference aim to shed light on the advancements achieved with SAB-142, which is currently positioned as a potentially best-in-class immunotherapy. This treatment focuses specifically on delaying the progression of Type 1 Diabetes (T1D) in newly diagnosed Stage 3 patients. Among the key points that will be highlighted in the presentation are:
- Comprehensive Phase 1 study data that validates the multi-specific mechanism of action of SAB-142.
- Findings from the Phase 1 study showcasing immunomodulation capabilities without causing sustained lymphodepletion after administration.
- Safety profiles from the Phase 1 research indicating that SAB-142 does not lead to serum sickness or the formation of anti-drug antibodies at the target dosing levels.
Expert Perspectives on SAB-142
According to Dr. Alexandra Kropotova, Chief Medical Officer of SAB BIO, "We are thrilled about the opportunity to present at another important international conference. Our focus on the compelling multi-specific mechanism of action of SAB-142 reinforces its potential to be a leading option in immunotherapy for T1D. We are eager to share additional findings from our Phase 1 studies and proceed with patient dosing in the Phase 2b SAFEGUARD trial soon."
Oral Presentation Details
The following details will guide attendees to the oral presentations scheduled for the conference:
Title: Mechanism of Action of a Fully Human Anti-Thymocyte Globulin, SAB-142, for the Treatment of Type 1 Diabetes
Session: 0730 – Orals 01: Pharmacotherapy and Safety, Drugs and Biologics | Presentation ID 21
Presenter: Christoph Bausch, PhD, EVP and COO, SAB BIO
Date and Time: Wednesday, December 10, 2025 | 17:00 - 17:12 SGT
Location: Room 326
E-Poster Presentations
Additionally, key e-poster presentations will be taking place:
Title: Immunomodulation without Sustained Lymphodepletion: SAB-142, a Fully Human Anti-Thymocyte Globulin
Session: 0650 – Short Oral 07: New Medications for Treating Obesity and Diabetes Part II | Presentation ID 94
Presenter: Stan Stoyanov, MD, VP, Clinical Development, SAB BIO
Date and Time: Wednesday, December 10, 2025 | 17:25 - 17:30 SGT
Location: Station 1
Title: Safety Profile of SAB-142; A Fully Human Anti-Thymocyte Globulin
Session: 0650 - Short Oral 07: New Medications for Treating Obesity and Diabetes Part II | Presentation ID 94
Presenter: Stan Stoyanov, MD, VP, Clinical Development, SAB BIO
Date and Time: Wednesday, December 10, 2025 | 15:35 - 15:40 SGT
Location: Station 1
About SAB-142
SAB-142 offers a promising pathway for patients with autoimmune Type 1 Diabetes. Characterized as a redosable immunotherapy, this treatment utilizes a multi-specific, fully human anti-thymocyte globulin (hATG) approach. This method targets several immune cells that contribute to the destruction of pancreatic beta cells, aiming to halt the assault on these essential insulin-producing cells.
About SAB BIO
SAB BIO is on the forefront of developing therapeutic solutions aimed at treating and preventing immune and autoimmune disorders. Their leading candidate, SAB-142, seeks to revolutionize the T1D treatment landscape through a pioneering disease-modifying mechanism that could delay onset and impede disease progression in Stage 3 T1D patients. SAB BIO is leveraging advanced genetic engineering technology to produce high-potency human immunoglobulin G (hIgG) treatments, potentially extending its platform to address various unmet medical needs.
Frequently Asked Questions
What is SAB-142?
SAB-142 is a novel immunotherapy currently in clinical development designed to modify the progression of Type 1 Diabetes in patients.
What are the main objectives of SAB-142?
The main goal is to delay the progression of Type 1 Diabetes in newly diagnosed patients through a multi-specific mechanism.
Where will the presentations take place?
The presentations will be held at the Asian Conference on Innovative Therapies for Diabetes Management in Singapore.
Who is the Chief Medical Officer of SAB BIO?
The Chief Medical Officer of SAB BIO is Dr. Alexandra Kropotova.
What does SAB BIO focus on?
SAB BIO specializes in developing innovative therapies for autoimmune diseases, primarily through novel immunotherapies.
